The application provides a beta-TCP /
PLGA support sustained-release body loaded with Cu-based nanoscale
enzyme and a preparation method, a 3D model of a
microstructure of a
bone defect is established by measuring
bone structure parameters, and a personalized beta-TCP /
PLGA support is printed by using beta-TCP /
PLGA printing materials through a 3D bioprinter technology. The beta-TCP / PLGA support is immersed in a Cu-HCF nanoscale
enzyme solution, so that the beta-TCP / PLGA support is loaded with Cu-HCF nanoscale
enzyme, thereby preparing a Cu-HCF nanoscale enzyme beta-TCP / PLGA sustained-release support. In a tumor and inflammatory microenvironment, the enzyme reaction can selectively kill tumor and inflammatory cells, and can protect normal tissues, reduce the possibility of recurrence of bone tumors and
inflammation at the
bone defect, and avoid possible side effects of drugs on the
human body. As a kind of bionic bone support, the beta-TCP / PLGA sustained-release support has good
mechanical strength and biodegradability, and also has the effect of keeping a long-acting and stable
drug release, can improve the directionality and reduce the toxic side effects. The material cost of the beta-TCP / PLGA sustained-release support is moderate and relatively easy to prepare, and has good
mass production prospects and economic applicability.